Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson Earnings: Here is What You Need to Know

Johnson & Johnson Earnings ReportFrom New Brunswick, N.J., early Tuesday came the quarterly earnings report of Johnson & Johnson (JNJ), which showed revenue missed estimates but the earnings-per-share number beat estimates. The stock moved down more than 1 percent before the open Tuesday, and has slid another 10 cents to $68.35 per share during the morning trading session.

The company reported quarterly net profit of $1.41 billion, which was nearly half of the previous $2.78 billion in the same quarter of 2011, and its modified its overall 2012 fiscal-year earnings outlook to $5-$5.07 per share, down from the previous $5.17. The quarter EPS of $1.30 beat estimates by 1 cent, but the overall revenue number of $16.5 billion in the quarter missed expectations by $200 million (1 percent). Overall, the revenue number was down 0.7 percent from the same quarter last year – though the company blamed a 4.2 percent negative impact on currency rates for the decrease.

Worldwide consumer sales of $3.6 billion in the quarter was 4.6 percent below Q2 2011 levels, with a 5.2 percent negative currency impact offsetting an overall increase of 0.6 percent. The modified yearly EPS figure included currency rate changes and excluded special items.

“Our talented associates around the world are building a strong foundation for sustainable growth through meaningful innovations and an expanding global footprint,” said CEO Alex Gorsky. “Our pharmaceutical pipeline continued its strong momentum this quarter with the submission of several new drug applications, as well as strong growth from several recently launched products that meet critical patient needs. The completion of the Synthes acquisition also marks an important milestone in strengthening our leadership in key health care markets, creating a powerful portfolio of orthopaedic and neurological solutions to advance patient health and well-being.”

The news hasn’t gone over well on the Street, which affects hedge funds like Warren Buffet’s Berkshire Hathaway and Ken Fisher’s Fisher Asset Management, both of which has had significant stakes in JNJ. Berkshire owned $1.9 billion in stock at the end of March, while Fisher was in for $710 million – and increased its share stake by 6 percent in the quarter.

Loading Comments...